UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12.
Aaron Y LeeCecilia Sungmin LeeThomas ButtWen XingRobert L JohnstonUsha ChakravarthyCatherine EganToks AkereleMartin McKibbinLouise DowneySalim NathaClare BaileyRehna KhanRichard AntcliffAtul VarmaVineeth KumarMarie TsaloumasKaveri MandalGerald LiewPearse Andrew KeaneDawn SimCatey BunceAdnan Tufailnull nullPublished in: The British journal of ophthalmology (2015)
All eyes with baseline VA>6/12 maintained better mean VA than the eyes with baseline VA 6/12 to >6/24 at all time points for at least 2 years. The significantly better visual outcome in patients who were treated with good baseline VA has implications on future policy regarding the treatment criteria for nAMD patients' funding.
Keyphrases
- age related macular degeneration
- optical coherence tomography
- end stage renal disease
- newly diagnosed
- ejection fraction
- public health
- chronic kidney disease
- healthcare
- diabetic retinopathy
- peritoneal dialysis
- prognostic factors
- cataract surgery
- cross sectional
- patient reported outcomes
- vascular endothelial growth factor
- replacement therapy
- combination therapy